Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Eisai Co., Ltd., a Japanese pharmaceutical company headquartered in Tokyo, Japan, is set to roll out its novel, Leqembi, developed to treat Alzheimer's disease. The company is expected to give the first doses to 1,500 patients in China on the launch of this new medical product.
Growth Prediction After Leqembi's Release
According to Reuters, Eisai will also experience massive growth once the Leqembi officially hits the market. The new drug for Alzheimer's disease will first be available for Chinese patients later this year.
The pharma company's spokesperson explained that it anticipates growth to speed up even more in 2025 because the disease's diagnosis also changes. Moreover, the representative said that more suitable Alzheimer's blood tests will also be ready, and this will further help the company reach a more significant share of the Chinese market, where an estimated 17 million people were diagnosed with an early stage of Alzheimer's.
"China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer's disease for Eisai," Eisai's spokesman stated. "The potential growth for Leqembi in China is huge."
Price and Eligibility
Eisai plans to release Leqembi in China and sell it for 200,000 yuan or around $28,180 annually. The company said it has not yet decided if it will ask for government coverage and will only do so after assessing the demand in the private market. If Eisai pushes through, it will be included on China's National Reimbursement Drug List, and prices could be reduced.
To be eligible for treatment with Eisai's Leqembi, patients must undergo cognitive and genetic testing to determine whether they have a gene that increases the drug's adverse side effects.
They must also go through testing to see if they have abnormal levels of amyloid. Once the treatment begins, all patients will still undergo a series of MRI scans to detect any potential fatal swelling and bleeding in the brain.
Approval of LEQEMBI By the FDA
The FDA approved Eisai's Leqembi in July 2023 to treat Alzheimer's Disease. According to the press release, it is the first and only approved treatment that has been able to lessen the rate of the disease's progression. The drug can also slow down cognitive and functional decline in adult patients.
Photo by: Eisai Website
